A Selective β-Catenin-Metadherin/CEACAM1-CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor-Macrophage Interaction.
Animals
Antigens, CD
Carcinoembryonic Antigen
/ metabolism
Cell Adhesion Molecules
Cell Line, Tumor
Chemokine CCL3
/ metabolism
Humans
Macrophages
/ metabolism
Mice
Neoplasm Recurrence, Local
/ metabolism
Transcription Factors
/ metabolism
Tumor Microenvironment
Wnt Signaling Pathway
/ physiology
beta Catenin
/ genetics
cytokinesis
ovarian cancer
polyploid
tumor-associated macrophages
β-catenin
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
31
01
2022
received:
27
07
2021
pubmed:
12
4
2022
medline:
9
6
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
Tumor heterogeneity plays a key role in cancer relapse and metastasis, however, the distinct cellular behaviors and kinetics of interactions among different cancer cell subclones and the tumor microenvironment are poorly understood. By profiling an isogenic model that resembles spontaneous human ovarian cancer metastasis with an highly metastatic (HM) and non-metastatic (NM) tumor cell pair, one finds an upregulation of Wnt/β-catenin signaling uniquely in HM. Using humanized immunocompetent mice, one shows for the first time that activated β-catenin acts nonautonomously to modulate the immune microenvironment by enhancing infiltrating tumor-associated macrophages (TAM) at the metastatic site. Single-cell time-lapse microscopy further reveals that upon contact with macrophages, a significant subset of HM, but not NM, becomes polyploid, a phenotype pivotal for tumor aggressiveness and therapy resistance. Moreover, HM, but not NM, polarizes macrophages to a TAM phenotype. Mechanistically, β-catenin upregulates cancer cell surface metadherin, which communicates through CEACAM1 expressed on macrophages to produce CCL3. Tumor xenografts in humanized mice and clinical patient samples both corroborate the relevance of enhanced metastasis, TAM activation, and polyploidy in vivo. The results thus suggest that targeting the β-catenin-metadherin/CEACAM1-CCL3 positive feedback cascade holds great therapeutic potential to disrupt polyploidization of the cancer subclones that drive metastasis.
Identifiants
pubmed: 35403834
doi: 10.1002/advs.202103230
pmc: PMC9165500
doi:
Substances chimiques
Antigens, CD
0
CD66 antigens
0
Carcinoembryonic Antigen
0
Ccl3 protein, mouse
0
Ceacam1 protein, mouse
0
Cell Adhesion Molecules
0
Chemokine CCL3
0
Transcription Factors
0
beta Catenin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2103230Subventions
Organisme : Hong Kong Research Grant Council GRF
ID : 17104820
Organisme : Hong Kong Research Grant Council GRF
ID : 17141216
Organisme : Laboratory for Synthetic Chemistry and Chemical Biology
Organisme : Hong Kong Research Grant Council CRF
ID : C2006-17E
Organisme : Hong Kong Research Grant Council CRF
ID : C4041-17G
Organisme : Croucher Foundation Senior Research Fellowship
Informations de copyright
© 2022 The Authors. Advanced Science published by Wiley-VCH GmbH.
Références
Science. 2012 Sep 28;337(6102):1678-84
pubmed: 23019653
Cancer Discov. 2014 Feb;4(2):175-185
pubmed: 24436049
Curr Drug Targets. 2010 Oct;11(10):1341-50
pubmed: 20840077
Methods Mol Biol. 2010;605:189-203
pubmed: 20072882
PLoS One. 2014 Apr 14;9(4):e94476
pubmed: 24732363
Histopathology. 2012 May;60(6):953-63
pubmed: 22372608
Semin Cancer Biol. 2022 Jun;81:145-159
pubmed: 33276091
Adv Exp Med Biol. 2020;1231:13-21
pubmed: 32060842
Cancer Cell. 2004 Apr;5(4):365-74
pubmed: 15093543
Nanomedicine (Lond). 2020 Jul;15(16):1585-1597
pubmed: 32669025
Oncoimmunology. 2017 May 16;6(7):e1328336
pubmed: 28811966
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3020-5
pubmed: 24516128
Front Immunol. 2015 Jun 25;6:330
pubmed: 26124761
Nat Rev Immunol. 2006 Jun;6(6):433-46
pubmed: 16724098
J Biol Chem. 2002 Mar 1;277(9):7438-46
pubmed: 11751883
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
J Exp Med. 2015 Jun 29;212(7):1043-59
pubmed: 26056232
J Immunol. 2004 Mar 1;172(5):2731-8
pubmed: 14978070
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Nat Cell Biol. 2014 Nov;16(11):1105-17
pubmed: 25266422
Front Oncol. 2019 May 03;9:349
pubmed: 31131259
Immunol Res. 2009 Dec;45(2-3):185-94
pubmed: 19253004
Nat Commun. 2018 Sep 20;9(1):3826
pubmed: 30237493
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Adv Cancer Res. 2013;120:1-38
pubmed: 23889986
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Mol Oncol. 2014 May;8(3):469-82
pubmed: 24444656
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Am J Cancer Res. 2012;2(5):566-80
pubmed: 22957308
Nat Rev Cancer. 2013 Apr;13(4):273-82
pubmed: 23426401
Adv Sci (Weinh). 2022 May;9(16):e2103230
pubmed: 35403834
Nat Rev Drug Discov. 2014 Jul;13(7):513-32
pubmed: 24981364
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Nat Rev Immunol. 2009 Apr;9(4):259-70
pubmed: 19282852
Clin Cancer Res. 2002 Apr;8(4):1108-14
pubmed: 11948121
Cancer Res. 2011 Feb 15;71(4):1497-505
pubmed: 21303980
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32478376
Cancer Res. 2014 Sep 15;74(18):5336-47
pubmed: 25074613
J Immunol. 2008 Nov 1;181(9):6384-93
pubmed: 18941229
Oncogene. 2017 Oct 26;36(43):5927-5938
pubmed: 28650464
Tumour Biol. 2014 Apr;35(4):3079-85
pubmed: 24234336
EMBO J. 2012 Jun 13;31(12):2714-36
pubmed: 22617422
Mol Cancer Ther. 2016 Jan;15(1):48-59
pubmed: 26586723
Mol Cancer Res. 2013 Nov;11(11):1326-36
pubmed: 24008673
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Adv Sci (Weinh). 2019 Jun 21;6(17):1900101
pubmed: 31508270
Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1913-1918
pubmed: 29434041
Cells. 2020 May 22;9(5):
pubmed: 32456078
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Clin Cancer Res. 2018 Mar 15;24(6):1415-1425
pubmed: 29288236
Nat Rev Mol Cell Biol. 2004 Jan;5(1):45-54
pubmed: 14708009
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
Br J Cancer. 2020 Apr;122(8):1219-1230
pubmed: 32099096
Front Oncol. 2014 May 26;4:123
pubmed: 24904834
Cancer Res. 2007 Jun 15;67(12):5708-16
pubmed: 17575137
Nat Rev Cancer. 2005 May;5(5):355-66
pubmed: 15864277